News and update on canine symmetrical lupoid onychodystrophy

Symmetrical lupoid onychodystrophy affects all claws on all four limbs within a matter of weeks, transforming the focal detachment of a single claw into a painful generalised condition. Described primarily in the Gordon Setter, where prevalence reaches 12.6%, and in the Bearded Collie, where it is on the rise, it remains the most common immune-mediated nail disorder in dogs. This review details recent data, from the genetic substrate to current therapeutic strategies.

1. Definition, terminology and epidemiology

1.1 Epidemiological data

The condition remains rare in the general canine population, but is concentrated in a few breeds with high prevalence rates. A survey conducted amongst 104 Norwegian owners of Gordon and English Setters estimated the prevalence at 12.6% in these breeds (Gershony 2019b). In the Giant Schnauzer, a prevalence of approximately 10% has been reported. In the Bearded Collie, health records indicate a frequency of 3.6% across 3,072 dogs surveyed, with an upward trend across successive surveys. This inter-breed gradient, which contrasts with the rarity of the disease in crossbred dogs, points strongly towards a genetic determinism of susceptibility.

Age of onset ranges from approximately two to seven years, with a mean close to 4.5 years (Wilbe 2010). In a cohort of Bearded Collies undergoing genomic sequencing, age at diagnosis ranged from 20 months to 7 years, confirming this young-to-mature adult profile (Gershony 2021). No clear sex predisposition has emerged from published series: in the cohort of 28 affected Bearded Collies, the distribution between males and females did not differ from that of controls (Steimer 2019). Breed distribution, however, is consistent across studies and constitutes the most robust epidemiological marker. The familial nature of the condition, with marked differences in incidence between lines and an increased risk in relatives of affected dogs, argues for substantial heritability, even though the mode of transmission has never been formally established (Wilbe 2010). The breed spectrum has broadened over successive publications: in addition to the historically described breeds, the condition has been reported in the Labrador, Welsh Corgi, Boxer and German Shorthaired Pointer, suggesting a susceptibility distributed across genetically distinct populations (Gershony 2019a).

1.2 Nosological context and position within the classification of nail diseases

Nail diseases are classically divided into traumatic, infectious, neoplastic, metabolic and immune-mediated conditions. Within this framework, symmetrical lupoid onychodystrophy occupies a singular position: it constitutes the most common immune-mediated condition of the canine nail complex, and the only one in which involvement is restricted to the claws without associated cutaneous or systemic signs (Wilbe 2010). This anatomical restriction sets it apart from generalised autoimmune dermatoses, such as pemphigus foliaceus or systemic lupus erythematosus, in which nail involvement is merely one feature amongst many.

The understanding of the disease has evolved since its initial description. The retrospective study of 18 cases observed between 1989 and 1993 established the histopathological picture, characterised by hydropic and lichenoid interface dermatitis, and coined the nomenclature on account of its resemblance to lupus (Scott 1995). The syndrome was initially regarded as a standalone descriptive entity. Subsequent work reconsidered it as a common reaction pattern of the claw, potentially triggered by atopic dermatitis, adverse food reaction, autoimmune dermatosis, or, more rarely, a drug reaction (Steimer 2019). From 1995 to 2026, the disease thus progressed from the status of an isolated syndrome to that of a multifactorial disorder, in which a genetic susceptibility linked to the major histocompatibility complex encounters environmental and immunological factors. This interpretation accounts for the heterogeneity of therapeutic responses and the difficulty in proposing a single unified protocol.

2. Pathophysiology and genetic basis

2.1 Immunological mechanisms involved

The autoimmune hypothesis rests on a body of converging evidence. Histologically, affected claws display a band-like mononuclear cell infiltrate running parallel to the basement membrane, hydropic degeneration and apoptosis of basal keratinocytes of the epidermis, and pigmentary incontinence in the dermis (Wilbe 2010). This lichenoid interface pattern is the hallmark lesion of the disease and underpins the term lupoid. The interface reaction reflects a lymphocyte-mediated assault on basal cells, a mechanism shared with several autoimmune dermatoses of the dermo-epidermal junction.

The strongest experimental argument comes from the genetics of the major histocompatibility complex. In the dog, this complex is known as the DLA and comprises three highly polymorphic class II genes, DLA-DRB1, DLA-DQA1 and DLA-DQB1, whose exon 2 encodes the antigen-binding domain (Wilbe 2010). The association of particular DLA class II haplotypes with the disease supports an aberrant antigen presentation leading to a breakdown of tolerance, a well-established mechanism in human autoimmune conditions linked to the HLA system. The human nail apparatus, like the hair follicle, constitutes a site of immune privilege characterised by low or absent expression of certain major histocompatibility complex antigens; a disruption of this privilege could contribute to the initiation of the nail interface reaction. The therapeutic argument completes the picture: the response to glucocorticoids and immunomodulators supports the immune nature of the process.

Adaptive immunity occupies the foreground in the accepted pathophysiological model. Major histocompatibility complex class II molecules participate in thymic selection of T lymphocytes by eliminating autoreactive clones; certain haplotypes may contribute to autoimmunity by failing to suppress these clones, which then escape central tolerance (Gershony 2021). The arginine substitution could alter the repertoire of presented peptides and favour the presentation of as yet unidentified nail autoantigens (Wilbe 2010). The nail interface reaction would thus reflect a lymphocytic assault targeting basal keratinocytes of the matrix and nail bed, mediated by T cells activated in contact with DLA class II molecules. This interpretation aligns the disease with human lichenoid conditions, in which a lymphocytic interface infiltrate destroys the epithelial basal layer. The pigmentary incontinence observed in the superficial dermis is a consequence of this basal destruction, with released melanosomes being phagocytosed by dermal macrophages.

2.2 Genetic determinism

Sequencing of exon 2 of the three DLA class II genes in 98 affected Gordon Setters and 98 controls identified a risk haplotype present in 52.6% of cases versus 34.2% of controls (Wilbe 2010). Dogs homozygous for this haplotype showed an elevated risk, the odds ratio reaching 5.4 compared with dogs lacking the haplotype.

In the Bearded Collie, the largest published series, comprising 236 dogs of whom 50 were affected, confirmed two closely related risk haplotypes (Gershony 2019a). Affected dogs were more frequently homozygous than controls.

2.3 Triggering factors and suspected comorbidities

Several conditions have been proposed as triggers or modulators, without a causal relationship always being established. Atopic dermatitis, adverse food reactions, pemphigus foliaceus, lupus erythematosus and vasculitis are amongst the documented causes of lupoid onychomadesis, reinforcing the concept of a common reaction pattern (Steimer 2019). Autoimmune hypothyroidism has been suggested as a comorbidity, but no study has demonstrated a robust association: epidemiological coincidence remains the most cautious interpretation in the absence of conclusive quantitative data. In the Bearded Collie, 11.2% of surveyed dogs presented at least one autoimmune disease, situating the condition within a broader breed-specific autoimmune background (Gershony 2019a).

Food allergy occupies a particular place as a modulating factor. In the Bearded Collie cohort, two dogs responded favourably to an elimination diet, one without additional treatment and the other alongside concurrent fatty acid supplementation; as the owners refused rechallenge, a diagnosis of adverse food reaction could not be confirmed, and the claws did not return to fully normal (Steimer 2019). The randomised trial comparing ciclosporin with fish oil in Setters, all fed for six months on a diet rich in fatty acids, showed no significant difference between groups, leading to the suggestion that dietary management itself, rather than the tested molecule, might account for the improvement (Hunter 2020). The vaccine hypothesis, long suspected, has not been confirmed: in the Munich series, only one dog developed onychomadesis within a month of vaccination, without a clear temporal correlation across the group as a whole. Secondary infections, bacterial or with Malassezia, perpetuate and aggravate the inflammatory process of the nail bed, justifying their systematic management, without constituting the primary cause.

Involvement of several digits on the same foot is common

3. Clinical presentation and differential diagnosis

3.1 Semiology and natural history

The initial phase is characterised by the detachment of one or a few claws, accompanied by onychia and lameness, sometimes preceded by periungual bleeding (Wilbe 2010). This deceptively focal presentation frequently leads to an erroneous diagnosis of trauma in general practice. Pain, repeated licking and reluctance to bear weight are warning signs that should prompt examination of all claws on all four limbs, as involvement of a single claw is rarely isolated in the long term.

The extension phase occurs over a few weeks to two or three months, during which onychomadesis progressively affects all claws on all four paws. The symmetry of the involvement, which gives the condition its name, then becomes apparent. The claws detach one after another, exposing a painful, exudative nail bed prone to secondary infection. Regrowth defines the chronic phase: new claws are short, dry, brittle and deformed, reflecting permanent onychodystrophy (Steimer 2019). Under treatment, many dogs cease to lose their claws, but these remain scaly, short and soft. Quality of life is affected to varying degrees; in the Bearded Collie cohort, impairment was mild in 11 cases, moderate in 5 and severe in 2. Residual fragility predisposes to localised recurrences and chronic discomfort, which determine long-term management.

The horny sheath in the process of separating from the fleshy part of the claw

 

After the claw falls off, the pain gradually subsides

3.2 Practical differential diagnosis

Isolated fungal and bacterial infections of the nail complex constitute the primary differential diagnosis. They typically affect one or a few claws, without the characteristic symmetry or generalisation, and cytology along with culture rapidly guide the clinician. Nail dermatophytosis, which is rare, or focal bacterial paronychia do not reproduce the simultaneous involvement of all four limbs. The distinction rests on topography, the uni- or multifocal nature, and the direct identification of infectious agents.

Systemic diseases with nail manifestations form the second group. Systemic lupus erythematosus, pemphigus foliaceus and vasculitis can cause onychomadesis, but are almost invariably accompanied by cutaneous, mucosal or systemic signs that are absent in the claw-limited form (Steimer 2019). The presence of depigmentation of the lips and eyelids, observed in one of the Bearded Collies in the Munich series, should raise suspicion of lupus or vitiligo and prompt biopsy of the depigmented skin. Common diagnostic pitfalls relate to the initial focal phase, which is confused with trauma, and to the fluctuating chronicity that may simulate spontaneous improvement. Indicators prompting referral to a specialist include symmetric and progressive involvement of multiple claws, failure to respond to local care, persistent pain, and any extra-nail sign that would broaden the picture towards a generalised autoimmune dermatosis.

3.3 Structured diagnostic approach

Cytology of the nail bed and direct examination constitute the essential first-line investigation, aimed at identifying and treating bacterial or Malassezia secondary infections before any aetiological conclusion is reached (van Amersfort 2023). This straightforward examination, performable in consultation, avoids attributing to the underlying disease signs that are being perpetuated by secondary colonisation. It guides antiseptic measures and topical antibiotherapy, and conditions the interpretation of subsequent steps.

The minimum laboratory work-up aims to rule out systemic disease and to identify comorbidities. Thyroid evaluation is warranted in the presence of any suggestive clinical sign, even though the association between hypothyroidism and nail disease remains unproven. Biopsy and histopathological examination provide diagnostic confirmation by revealing hydropic and lichenoid interface dermatitis, apoptosis of basal keratinocytes and pigmentary incontinence (Wilbe 2010). Two sampling methods are available. Amputation of the third phalanx, long considered the gold standard, provides a quality specimen including the matrix but permanently sacrifices a claw; matrix biopsy without onychectomy, which is less destructive, has been performed in several series (Hunter 2020). Diagnosis is often made on the basis of history, characteristic clinical signs and exclusion of other causes, with histological confirmation reserved for atypical or refractory cases: in the original retrospective study, only two of the five dogs in one series had histopathological confirmation, illustrating the pragmatic role of biopsy (Hunter 2020). In a research context, nail bed biopsy and gene expression profiling have been proposed to identify the genes actually involved, but their invasive nature limits their clinical application (Gershony 2021). In practice, the clinician prioritises investigations according to severity and atypicality: cytology systematically as first line, laboratory work-up in the presence of any extra-nail sign, and biopsy as a last resort when the diagnosis remains uncertain or the response to treatment is lacking. Amputation of the third phalanx is preferably reserved for a claw already compromised, so as not to sacrifice a functional claw, and submission of the fixed specimen to a laboratory familiar with nail dermatoses improves the relevance of histological interpretation.

4. Therapeutic strategies

4.1 Initial management and symptomatic measures

Pain dominates the acute phase and mandates analgesia. Reduction of mechanical trauma is achieved through regular clipping and filing of the claws to minimise stress; in one case of a Pointer crossbreed, mechanical management alone was sufficient to achieve lasting control of the condition after the first year, with no subsequent onychomadesis or pain (Hunter 2020). This conservative measure, sometimes sufficient in mild forms, invariably accompanies medical treatments.

Treatment of secondary infections constitutes the second pillar. Rigorous local antisepsis of the exposed nail bed and, when cytology warrants it, targeted antibiotherapy limit the perpetuation of inflammation (van Amersfort 2023). Responsible antibiotherapy in 2026 demands that systemic antibacterials be reserved for documented secondary infections and that topical care be favoured. Total nail avulsion under general anaesthesia has been proposed in the most painful and refractory cases: it immediately removes the source of pain by extracting all detached claws, but is a major procedure, the aftermath of which requires sustained analgesia and prolonged healing. This option remains exceptional and is only considered after the failure of medical and conservative approaches.

4.2 First- and second-line immunomodulatory treatments

The tetracycline–niacinamide combination represents a recognised first-line option, based on the immunomodulatory properties of these molecules. Tetracycline and nicotinamide have been administered at a dose of 500 mg of each molecule three times daily in dogs weighing more than 10 kg, with a good or partial response in several cases, the onset of action extending over several weeks (Hunter 2020). An evidence-based review identified 35 dogs treated with niacinamide and antibiotherapy for at least seven weeks, with a partial to excellent improvement in 12 of them (van Amersfort 2023). Comparative synthesis of available series yields no clearly superior drug class: tetracycline–niacinamide, doxycycline–niacinamide and pentoxifylline as monotherapy have each produced responses ranging from excellent to poor, with no demonstrated difference in efficacy between tetracycline and doxycycline (Hunter 2020). Doxycycline, being better tolerated and simpler to administer than tetracycline, has largely superseded it; a four-month course combining fatty acids, doxycycline and niacinamide was followed by complete remission maintained after discontinuation in one Bearded Collie (Steimer 2019). Concerns over responsible antibiotherapy in 2026 call for periodic reassessment of its justification; the risk of emergence of multidrug-resistant bacteria has indeed led to the recommendation that long-term tetracycline and doxycycline be replaced by pentoxifylline, considered to be of comparable efficacy.

Ciclosporin features amongst the second-line options. An unblinded randomised trial compared ciclosporin at 5 mg/kg once daily with fish oil supplementation in 12 Gordon Setters and one English Setter, all fed for six months on a diet rich in fatty acids, with no significant difference between groups (Hunter 2020). Ciclosporin may be used alone or in combination with fatty acids, its advantage lying in corticosteroid-sparing. Systemic corticotherapy retains recognised efficacy in severe forms. The adverse effects of long-term glucocorticoids and of azathioprine, used at 2.2 mg/kg per day, restrict these molecules to refractory cases: in the Munich series, one dog initially improved on azathioprine and prednisolone relapsed and was subsequently euthanised owing to persistent pain and lameness.

4.3 Adjuvant treatments and long-term management

Omega-3 fatty acid supplementation occupies a central place amongst adjuvants. The preparations used combine eicosapentaenoic acid and docosahexaenoic acid (Hunter 2020). Nine dogs supplemented with omega-3 and omega-6, at a dose of one capsule per 9.1 kg per day, showed a good to excellent response, with improvement at three to four months and maximum benefit within twelve months; two of them relapsed upon discontinuation but responded to reintroduction (Scott 1995). At least partial response to fatty acids was recorded in six of the seven studies that evaluated them, justifying their use as an adjuvant or maintenance treatment despite the absence of proof of universal efficacy.

Pentoxifylline features in the most widely used combinations, the trio of fatty acids, pentoxifylline and tetracycline being the most common in the Bearded Collie cohort (Steimer 2019). Like tetracycline, it inhibits the expression of matrix metalloproteinases, and the nail lesional process shares similarities with laminitis in ungulates, in which the transcription of a membrane metalloproteinase is implicated, which may justify its use as an alternative to antibiotics. The doses employed in published series have not, however, been standardised or systematically reported, so that no reference dosage can be cited from the literature specific to this condition (Hunter 2020). Vitamin E, administered at 400 mg twice daily, accompanied corticosteroid protocols with a response judged good to excellent in a small series (Scott 1995). Biotin and zinc, on the other hand, provided no improvement in the cases in which they were tried, and the combination of B-group vitamins and zinc had no effect after five months in one dog (van Amersfort 2023). The overall evidence in favour of nutraceuticals remains weak; these products may improve signs or reduce the dose of concomitant medication through a sparing effect without constituting a disease-modifying treatment. Therapeutic maintenance is based on dose adjustment guided by clinical response: reduction in the use of doxycycline and niacinamide, continuation of fatty acids, and regular monitoring of claw condition and pain. The largest published retrospective therapeutic series, comprising 30 dogs of various breeds and sizes, confirmed this logic of individualised combinations without a single unified protocol (Hunter 2020).

5. Prognosis, follow-up and perspectives

5.1 Assessment of therapeutic response

Objective response criteria are based on the restored anchoring of the horny sheath, the absence of periungual inflammation and the resolution of pain. An excellent response corresponds to regrowth of normal claws; a good response to resolution of onycholysis, onychomadesis and pain despite persistence of abnormal morphology; a partial response combines residual onychodystrophy with infrequent episodes of detachment; and failure denotes the absence of improvement. This grading, used in published series, structures assessment in the consultation setting.

The kinetics of nail regrowth necessitate appropriately timed assessment. The slow growth rate of the canine claw explains why benefit is only appreciable after several months, with improvement typically occurring at three to four months and the maximum within twelve months (Scott 1995). Premature assessment of treatment, judged over a few weeks, would erroneously lead to a conclusion of failure. In the Bearded Collie cohort, 19 dogs ceased to lose their claws even though these remained scaly, short and soft, a state considered an acceptable clinical success even without complete morphological restitution (Steimer 2019). This nuance, essential when counselling the owner, refocuses the objective on comfort and function rather than on nail aesthetics.

5.2 Long-term prognosis and factors influencing outcome

The prognosis is generally favourable with regard to comfort but guarded with regard to morphological recovery. Of 25 treated Bearded Collies, improvement was achieved in 17, judged good in 13 and excellent in 4 (Steimer 2019). Relapses are frequent, underscoring the frequent need for prolonged maintenance treatment, sometimes lifelong. Discontinuation of treatment exposes the patient to relapse, with several dogs regaining remission only after reintroduction of supplementation (Scott 1995).

Early diagnosis influences the quality of regrowth and animal comfort. Management initiated during the extension phase, before the establishment of severe chronic onychodystrophy, offers better prospects for functional claws. Conversely, a longstanding and neglected condition leaves morphological sequelae that are difficult to correct. Available data do not permit the establishment of a reliable differential prognosis according to breed: published series involve limited numbers, often of a single breed, and there is no significant association between the type of molecule used and outcome. The Bearded Collie, Gordon Setter and German Shepherd share a comparable clinical picture and therapeutic response, without any breed clearly distinguished by a worse prognosis on the basis of current data. The absence of an association between the nature of the molecule and outcome suggests that the quality of overall management, combining control of secondary infections, mechanical care and prolonged compliance, carries more weight than the choice of a particular immunomodulator. The genetic profile may in time refine the prognosis: dogs homozygous for two DLA risk haplotypes, who concentrate the highest susceptibility, might present with an earlier or more persistent disease (Gershony 2021).

Conclusion

Symmetrical lupoid onychodystrophy is now understood as an immune-mediated reaction pattern of the claw, whose susceptibility rests on DLA class II haplotypes shared amongst predisposed breeds. Diagnosis combines recognition of symmetric and progressive onychomadesis, exclusion of infectious and systemic causes, and, in atypical cases, histological confirmation of lichenoid interface dermatitis. Management, which is multimodal and prolonged, targets comfort and function rather than morphological restitution, with the doxycycline–niacinamide combination and fatty acid supplementation constituting the first-line pillars, and immunosuppressants reserved for refractory forms. Frequent relapses necessitate long-term follow-up.

References